GlobeNewswire: Immune Design Corp. Contains the last 10 of 117 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T02:16:41ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/12/02/1660421/0/en/Immune-Design-Reports-Increased-Overall-Response-Rate-and-Longer-Progression-Free-Survival-of-Patients-with-Follicular-Lymphoma-Treated-in-a-Randomized-Trial-with-a-Combination-Reg.html?f=22&fvtc=4&fvtv=15826Immune Design Reports Increased Overall Response Rate and Longer Progression Free Survival of Patients with Follicular Lymphoma Treated in a Randomized Trial with a Combination Regimen of G100 and Pembrolizumab 2018-12-02T17:00:00Z<![CDATA[SEATTLE and SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 02, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced long-term follow up results from a randomized Phase 2 clinical trial of 10 ug intratumoral G100, a TLR4 agonist, with or without pembrolizumab, in follicular lymphoma patients.]]>https://www.globenewswire.com/news-release/2018/11/20/1654429/0/en/Immune-Design-to-Present-at-Piper-Jaffray-30th-Annual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=15826Immune Design to Present at Piper Jaffray 30th Annual Healthcare Conference2018-11-20T13:00:00Z<![CDATA[SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that management will present at the Piper Jaffray 30th Annual Healthcare Conference on Tuesday, November 27, 2018 at 2:30 p.m. Eastern in New York.]]>https://www.globenewswire.com/news-release/2018/11/09/1648935/0/en/Immune-Design-to-Present-at-Jefferies-2018-London-Healthcare-Conference.html?f=22&fvtc=4&fvtv=15826Immune Design to Present at Jefferies 2018 London Healthcare Conference2018-11-09T13:00:00Z<![CDATA[SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies 2018 London Healthcare Conference on Wednesday, November 14, 2018 at 9:40 a.m. GMT / 4:40 a.m. ET.]]>https://www.globenewswire.com/news-release/2018/11/06/1646406/0/en/Immune-Design-Reports-Third-Quarter-2018-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=15826Immune Design Reports Third Quarter 2018 Financial Results and Provides Corporate Update2018-11-06T21:01:00Z<![CDATA[Conference call at 1:30 pm Pacific today]]>https://www.globenewswire.com/news-release/2018/11/06/1645996/0/en/Immune-Design-Announces-Multiple-G100-Presentations-at-the-Society-for-Immunotherapy-of-Cancer-Meeting-SITC-Annual-Meeting.html?f=22&fvtc=4&fvtv=15826Immune Design Announces Multiple G100 Presentations at the Society for Immunotherapy of Cancer Meeting (SITC) Annual Meeting2018-11-06T13:01:00Z<![CDATA[SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced multiple presentations showcasing G100, its potent intratumoral TLR4 agonist, at the annual meeting for the Society for Immunotherapy of Cancer (SITC) being held in Washington D.C. this week. The presentations, which include both clinical and preclinical study data, further support the activity of G100 in follicular lymphoma patients and the potential combinability of G100 with other novel immune-modulatory agents.]]>https://www.globenewswire.com/news-release/2018/10/30/1639019/0/en/Immune-Design-to-Report-Third-Quarter-2018-Financial-Results-and-Provide-Corporate-Update.html?f=22&fvtc=4&fvtv=15826Immune Design to Report Third Quarter 2018 Financial Results and Provide Corporate Update2018-10-30T12:00:00Z<![CDATA[SEATTLE and SOUTH SAN FRANCISCO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report third quarter 2018 financial results after the close of U.S. financial markets on Tuesday, November 6, 2018. Immune Design management will host a webcast conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on November 6, 2018 to discuss the financial results and provide a corporate update.]]>https://www.globenewswire.com/news-release/2018/10/11/1620277/0/en/Immune-Design-Announces-Program-Updates-Portfolio-Prioritization-for-G100-and-CMB305.html?f=22&fvtc=4&fvtv=15826Immune Design Announces Program Updates & Portfolio Prioritization for G100 and CMB3052018-10-11T20:01:00Z<![CDATA[SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced program updates for its G100 intratumoral TLR4 agonist and CMB305 cancer vaccine programs in development for the treatment of cancer.]]>https://www.globenewswire.com/news-release/2018/08/30/1563312/0/en/Immune-Design-to-Present-at-Upcoming-September-Investor-Conferences.html?f=22&fvtc=4&fvtv=15826Immune Design to Present at Upcoming September Investor Conferences2018-08-30T12:00:00Z<![CDATA[SEATTLE and SOUTH SAN FRANCISCO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on novel therapies in oncology, today announced that senior management will present at the following upcoming investor conferences:]]>https://www.globenewswire.com/news-release/2018/08/01/1545765/0/en/Immune-Design-Reports-Second-Quarter-2018-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=15826Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update2018-08-01T20:01:00Z<![CDATA[SEATTLE, WA and SOUTH SAN FRANCISCO, CA, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today reported financial results and a corporate update for the second quarter ended June 30, 2018.]]>https://www.globenewswire.com/news-release/2018/07/25/1541839/0/en/Immune-Design-to-Report-Second-Quarter-2018-Financial-Results-and-Provide-Corporate-Update.html?f=22&fvtc=4&fvtv=15826Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update2018-07-25T12:00:00Z<![CDATA[SEATTLE and SOUTH SAN FRANCISCO, Calif., July 25, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report second quarter 2018 financial results after the close of U.S. financial markets on Wednesday, August 1, 2018. Immune Design management will host a webcast conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2018 to discuss the financial results and provide a corporate update.]]>